跳至主要内容
临床试验/NCT01363466
NCT01363466终止3 期

Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer

UNICANCER70 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2003年5月最近更新:
适应症

试验速览

阶段
3 期
状态
终止
发起方
UNICANCER
入组人数
61
试验地点
70
主要终点
Relapse free survival

研究概览

简要总结

GYNECO 02 hypothesis is that hysterectomy reduces the possibility of local or loco-regional relapse, especially in patient with a reduced metastatic risk and who received a local chemoradiation therapy with an increase of radiotherapy doses (45 grays).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • operable Stage IB2/II Cervical Cancer
  • adenocarcinoma, squamous cell or adenosquamous carcinoma
  • Patient between 18 and 70 years old
  • No lombo-aortic lymph node invasion at baseline
  • Previous 45 grays external pelvic radiation with concomitant chemotherapy (cisplatin 40 mg/m2/week corresponding to 5 cycles)
  • Followed by a 15 grays utero-vaginal brachytherapy, eventually combined with a 6th cycle of chemotherapy (cisplatin 40 mg/m2)
  • with a pelvic boost if lymph node or parametrial invasion
  • No macroscopic residual tumor after 6 to 8 weeks after brachytherapy.

排除标准

  • Other tumor histology (neuro-endocrine)
  • Stage > II (FIGO 1995) at baseline
  • Patient with remaining cervical cancer (after sub-total hysterectomy)

结局指标

主要结局

Relapse free survival

时间窗: from randomization to relapse or last contact (up to 3 years)

There is a follow-up period of 3 years.

次要结局

  • Overall Survival(From randomisation to death or last contact (up to 3 years))

研究者

发起方
UNICANCER
申办方类型
Other

研究点 (70)

Loading locations...

相似试验